Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 14/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17034646 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18652242 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Water SCHEMBL28772063 | 0.99 | SLC5A2 (0.98) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14065540 | 0.91 | SLC5A2 (0.83) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14108309 | 0.90 | SLC5A2 (0.82) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14147833 | 0.89 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2864607 | 0.89 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL15938369 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14248212 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14248214 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| US-20210283156-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-09-16 | — | — | US | claimed |
| US-20200069713-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2020-03-05 | — | — | US | claimed |
| US-20170020907-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-01-26 | — | — | US | claimed |
| EP-3106156-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2016-12-21 | — | — | EP | claimed |
| US-20160158264-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-06-09 | — | — | US | claimed |
| EP-2846797-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8846613-B2 | Pharmaceutical combinations for the treatment of metabolic disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | claimed |
| EP-2698152-A1 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | Boehringer Ingelheim International GmbH (DE) | 2014-02-19 | — | — | EP | claimed |
| US-20140038888-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | claimed |
| US-20100298243-A1 | COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | claimed |
| WO-2010092123-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | WO | claimed |
| EP-2187879-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | claimed |
| CN-101238112-A | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments | BOEHRINGER INGELHEIM INT (DE) | 2008-08-06 | — | — | CN | claimed |
| EP-1926720-A1 | CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2008-06-04 | — | — | EP | claimed |
| WO-2007028814-A1 | CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-15 | — | — | WO | claimed |
| US-20070054867-A1 | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 401/4885 |
| US-20170020907-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20100298243-A1 | COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | SLC5A1, SLC5A2, GLP1R | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 373/4885 |
| US-20210283156-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20200069713-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20070054867-A1 | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments | MGAT3, ALB, MGAT2 | SLC5A2 15/4885SLC5A1 9/4885ADRA2A 1358/4885 |
| US-20140038888-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | SLC5A1, SLC5A2, CPT1A | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 168/4885 |
| US-20160158264-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.